Inspire Advisors’s Alaunos Therapeutics TCRT Stock Holding History

Inspire Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1	Closed	–	–	640
2020 Q4	$0	Buy	+1	New	+$398	﹤0.01%	813

Other funds holding TCRT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Inspire Advisors's TCRT Position: Q1 2021 in Review

Inspire Advisors sold out of Alaunos Therapeutics (TCRT) in Q1 2021, closing a stake of 1 share.

Inspire Advisors first reported a position in TCRT in Q4 2020 and held it in 1 quarter. The position peaked at $0 in Q4 2020. 151 funds tracked by Wall St. Rank hold TCRT as of Q1 2021.

Inspire Advisors reported no remaining Alaunos Therapeutics position as of Q1 2021 after selling out during the quarter.
Inspire Advisors sold 1 Alaunos Therapeutics share in Q1 2021.
Inspire Advisors first reported a position in Alaunos Therapeutics in Q4 2020 and held it in 1 quarter.
Inspire Advisors's Alaunos Therapeutics position peaked at $0 in Q4 2020.
151 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2021.

Based on Inspire Advisors's 13F filing for Q1 2021, filed 30 Apr 2021.